CEL-SCI Reports 73.4% Five-Year Survival With Multikine in Selected Patients
CEL-SCI reported five-year survival of 73.4% among biomarker-selected head and neck cancer patients treated with Multikine.
CEL-SCI reported five-year survival of 73.4% among biomarker-selected head and neck cancer patients treated with Multikine.